norfloxacin has been researched along with Liver Cirrhosis in 81 studies
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.
norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.
Liver Cirrhosis: Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Primary norfloxacin prophylaxis effectively prevents bacterial infections in patients with ACLF." | 9.51 | Primary Norfloxacin Prophylaxis for APASL-Defined Acute-on-Chronic Liver Failure: A Placebo-Controlled Double-Blind Randomized Trial. ( Fatima, S; Gora, BA; Gujjarlapudi, D; Gupta, R; Kulkarni, AV; Kumar, K; Premkumar, M; Rao, PN; Rapole, B; Reddy, DN; Sasikala, M; Sharma, M; Simhadri, V; Tirumalle, S; Yelamanchili, S, 2022) |
| "For the prevention of spontaneous bacterial peritonitis (SBP) in cirrhotic patients with ascites, norfloxacin 400 mg per day is recommended as a standard regimen." | 9.27 | Daily Norfloxacin vs. Weekly Ciprofloxacin to Prevent Spontaneous Bacterial Peritonitis: A Randomized Controlled Trial. ( Jang, JY; Jung, YK; Kim, BI; Kim, HS; Kim, YS; Lee, YR; Park, SY; Seo, YS; Suh, SJ; Um, SH; Yim, HJ; Yim, SY, 2018) |
| "Two hundred and sixty two cirrhotic patients with ascites and a previous episode of SBP were assigned randomly to receive either 1200 mg rifaximin or 400 mg of norfloxacin daily for 6 months." | 9.22 | Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis. ( Abd-Elsalam, S; Abo Ali, L; Elfert, A; Ibrahim, S; Soliman, S, 2016) |
| "Our aim was to compare weekly rufloxacin with daily norfloxacin in the secondary prophylaxis of spontaneous bacterial peritonitis and to examine changes in antibiotic susceptibility in fecal Escherichia coli." | 9.10 | Daily norfloxacin is more effective than weekly rufloxacin in prevention of spontaneous bacterial peritonitis recurrence. ( Bauer, TM; Bory, F; Clemente, G; Follo, A; Navasa, M; Planas, R; Rodés, J; Vaquer, P; Vargas, V; Vila, J, 2002) |
| "Long-term treatment with cisapride or antibiotics reversed altered small-intestinal motility and bacterial overgrowth in patients with liver cirrhosis." | 9.09 | Long-Term treatment with cisapride and antibiotics in liver cirrhosis: effect on small intestinal motility, bacterial overgrowth, and liver function. ( Cumsille, F; Defilippi, C; Hurtado, C; Madrid, AM; Venegas, M, 2001) |
| "Selective intestinal decontamination with norfloxacin is useful in the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding." | 9.08 | Parenteral antibiotic prophylaxis of bacterial infections does not improve cost-efficacy of oral norfloxacin in cirrhotic patients with gastrointestinal bleeding. ( Balanzó, J; Guarner, C; Kolle, L; Novella, MT; Ortiz, J; Pamplona, J; Sàbat, M; Sainz, S; Soriano, G; Torras, J; Villanueva, C, 1998) |
| "To assess the efficacy of selective intestinal decontamination with norfloxacin in the prevention of bacterial infections in cirrhotic patients with gastrointestinal hemorrhage, 119 patients were included in a prospective randomized study." | 9.07 | Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. ( Anguera, A; Balanzó, J; Cussó, X; González, D; Guarner, C; Sainz, S; Soriano, G; Tomás, A; Torras, X; Villanueva, C, 1992) |
| "Eighty cirrhotic patients who had recovered from an episode of spontaneous bacterial peritonitis were included in a multicenter, double-blind trial aimed at comparing long-term norfloxacin administration (400 mg/day; 40 patients) vs." | 9.06 | Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. ( Almela, M; Forné, M; Ginés, P; Llach, J; Marco, F; Miranda, ML; Planas, R; Rimola, A; Salmerón, JM; Vargas, V, 1990) |
| "For recipients who have received prophylactic norfloxacin, clinicians should be aware of the high risk of multidrug-resistant bacterial infections during the first month after liver transplant." | 8.31 | Impact of Prophylactic Norfloxacin in Multidrug Resistant Bacterial Infections in the Early Liver Posttransplant Period. ( Castells, L; Dopazo, C; Len, O; Lladó, L; Los-Arcos, I; Lung, M; Nuvials, X; Oriol, I; Pérez-Cameo, C; Sabé, N, 2023) |
| "In cirrhotic rats with ascites: (a) pentoxifylline as well as norfloxacin reduced intestinal bacterial overgrowth and bacterial translocation and prevented spontaneous bacterial peritonitis; (b) pentoxifylline, but not norfloxacin, reduced oxidative stress in cecal mucosal." | 7.78 | Effects of pentoxifylline on intestinal bacterial overgrowth, bacterial translocation and spontaneous bacterial peritonitis in cirrhotic rats with ascites. ( Acevedo, J; Brusasco, C; Corradi, F; Fernández, J; Fernández-Varo, G; Gines, P; Mosbah, IB; Navasa, M; Pelosi, P; Ramirez, MJ; Rocco, PR; Seva-Pereira, T; Silva, A; Vila, J, 2012) |
| "The extensive use of invasive procedures and of long-term norfloxacin prophylaxis in the management of cirrhotic patients may have influenced the epidemiology of bacterial infections in cirrhosis." | 7.71 | Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. ( Arroyo, V; Colmenero, J; Fernández, J; Gómez, J; Navasa, M; Rodés, J; Vila, J, 2002) |
| " There was no difference among the studied groups regarding the incidence and severity of adverse events reported." | 6.82 | Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: a prospective randomized open-label comparative multicenter study. ( Abdelaziz, A; Abdelrashed, M; Assem, M; El-Azab, G; Elemam, S; Elsabaawy, M; Hamed, W; Khodeer, S, 2016) |
| "Norfloxacin was not superior to other antibiotics." | 6.66 | Efficacy of Norfloxacin Prophylaxis to Prevent Spontaneous Bacterial Peritonitis: A Systematic Review and Meta-Analysis. ( Fernandez, J; Ferstl, PG; Graf, C; Herrmann, E; Lange, CM; Mücke, MM; Mücke, VT; Schwarzkopf, KM; Trebicka, J; Zeuzem, S, 2020) |
| "Primary norfloxacin prophylaxis effectively prevents bacterial infections in patients with ACLF." | 5.51 | Primary Norfloxacin Prophylaxis for APASL-Defined Acute-on-Chronic Liver Failure: A Placebo-Controlled Double-Blind Randomized Trial. ( Fatima, S; Gora, BA; Gujjarlapudi, D; Gupta, R; Kulkarni, AV; Kumar, K; Premkumar, M; Rao, PN; Rapole, B; Reddy, DN; Sasikala, M; Sharma, M; Simhadri, V; Tirumalle, S; Yelamanchili, S, 2022) |
| "These studies reported a 1-year recurrence rate of 20-26%." | 5.51 | Spontaneous bacterial peritonitis recurrence in patients with cirrhosis receiving secondary prophylaxis with norfloxacin. ( Barcán, LA; Bermudez, C; Diaz, JM; Dirchwolf, M; Gadano, AC; Giunta, D; Gutierrez-Acevedo, MN; Marciano, S; Smud, A, 2019) |
| "The SBP recurrence rate was 42." | 5.37 | Recurrence of spontaneous bacterial peritonitis in cirrhotic patients non-prophylactically treated with norfloxacin: serum albumin as an easy but reliable predictive factor. ( Chen, WT; Chiu, CT; Ho, YP; Huang, CH; Lin, CY; Lin, TN; Sheen, IS, 2011) |
| "We performed a 5-year retrospective study to evaluate the effect of long-term administration of norfloxacin on the epidemiology of severe hospital-acquired infections in patients with advanced cirrhosis." | 5.30 | Epidemiology of severe hospital-acquired infections in patients with liver cirrhosis: effect of long-term administration of norfloxacin. ( Campillo, B; Dupeyron, C; Leluan, G; Mangeney, N; Richardet, JP, 1998) |
| "For the prevention of spontaneous bacterial peritonitis (SBP) in cirrhotic patients with ascites, norfloxacin 400 mg per day is recommended as a standard regimen." | 5.27 | Daily Norfloxacin vs. Weekly Ciprofloxacin to Prevent Spontaneous Bacterial Peritonitis: A Randomized Controlled Trial. ( Jang, JY; Jung, YK; Kim, BI; Kim, HS; Kim, YS; Lee, YR; Park, SY; Seo, YS; Suh, SJ; Um, SH; Yim, HJ; Yim, SY, 2018) |
| "Two hundred and sixty two cirrhotic patients with ascites and a previous episode of SBP were assigned randomly to receive either 1200 mg rifaximin or 400 mg of norfloxacin daily for 6 months." | 5.22 | Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis. ( Abd-Elsalam, S; Abo Ali, L; Elfert, A; Ibrahim, S; Soliman, S, 2016) |
| " A total of 94 cirrhotic patients having large oesophageal varices without history of variceal bleeding were randomized to three treatment groups and given 2 months' treatment with propranolol plus placebo, propranolol plus antibiotics (norfloxacin 400 mg BD) or propranolol plus probiotic (VSL#3, 900 billion/day) randomly assigned in 1:1:1 ratio." | 5.17 | Effects of the adjunctive probiotic VSL#3 on portal haemodynamics in patients with cirrhosis and large varices: a randomized trial. ( Garg, V; Gupta, N; Kumar, A; Sarin, SK; Sharma, BC; Sharma, P, 2013) |
| "2 mg/dL, blood urea nitrogen level > or = 25 mg/dL, or serum sodium level < or = 130 mEq/L) were included in a randomized controlled trial aimed at comparing norfloxacin (35 patients) vs placebo (33 patients) in the primary prophylaxis of spontaneous bacterial peritonitis." | 5.12 | Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. ( Arroyo, V; Fernández, J; Ginès, P; Monfort, D; Montoliu, S; Navasa, M; Pardo, A; Planas, R; Quintero, E; Soriano, G; Such, J; Vargas, V; Vila, C, 2007) |
| " The probability of developing proved or possible infections, proved infections, and spontaneous bacteremia or spontaneous bacterial peritonitis was significantly higher in patients receiving norfloxacin (33% vs 11%, P = ." | 5.12 | Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. ( Arroyo, V; Durandez, R; Fernández, J; Gómez, C; Guarner, C; Navasa, M; Planas, R; Ruiz del Arbol, L; Serradilla, R, 2006) |
| "Our aim was to compare weekly rufloxacin with daily norfloxacin in the secondary prophylaxis of spontaneous bacterial peritonitis and to examine changes in antibiotic susceptibility in fecal Escherichia coli." | 5.10 | Daily norfloxacin is more effective than weekly rufloxacin in prevention of spontaneous bacterial peritonitis recurrence. ( Bauer, TM; Bory, F; Clemente, G; Follo, A; Navasa, M; Planas, R; Rodés, J; Vaquer, P; Vargas, V; Vila, J, 2002) |
| "Long-term treatment with cisapride or antibiotics reversed altered small-intestinal motility and bacterial overgrowth in patients with liver cirrhosis." | 5.09 | Long-Term treatment with cisapride and antibiotics in liver cirrhosis: effect on small intestinal motility, bacterial overgrowth, and liver function. ( Cumsille, F; Defilippi, C; Hurtado, C; Madrid, AM; Venegas, M, 2001) |
| "Selective intestinal decontamination with norfloxacin is useful in the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding." | 5.08 | Parenteral antibiotic prophylaxis of bacterial infections does not improve cost-efficacy of oral norfloxacin in cirrhotic patients with gastrointestinal bleeding. ( Balanzó, J; Guarner, C; Kolle, L; Novella, MT; Ortiz, J; Pamplona, J; Sàbat, M; Sainz, S; Soriano, G; Torras, J; Villanueva, C, 1998) |
| "Selective intestinal decontamination (SID) for 7 days with norfloxacin (NF) was performed in 15 patients with schistosomal hepatic fibrosis (SHF) and low-protein ascites." | 5.07 | Selective intestinal decontamination in patients with schistosomal hepatic fibrosis and low-protein ascites. ( Abou Seif Helmy, M; el Aggan, HA; el-Aggan, HA; Guirguis, TG, 1993) |
| "To assess the efficacy of selective intestinal decontamination with norfloxacin in the prevention of bacterial infections in cirrhotic patients with gastrointestinal hemorrhage, 119 patients were included in a prospective randomized study." | 5.07 | Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. ( Anguera, A; Balanzó, J; Cussó, X; González, D; Guarner, C; Sainz, S; Soriano, G; Tomás, A; Torras, X; Villanueva, C, 1992) |
| "Eighty cirrhotic patients who had recovered from an episode of spontaneous bacterial peritonitis were included in a multicenter, double-blind trial aimed at comparing long-term norfloxacin administration (400 mg/day; 40 patients) vs." | 5.06 | Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. ( Almela, M; Forné, M; Ginés, P; Llach, J; Marco, F; Miranda, ML; Planas, R; Rimola, A; Salmerón, JM; Vargas, V, 1990) |
| "The use of norfloxacin either as primary or secondary prophylaxis of bacterial infections in advanced cirrhosis has improved patient's survival." | 4.91 | Immunomodulating effects of antibiotics used in the prophylaxis of bacterial infections in advanced cirrhosis. ( Francés, R; González-Navajas, JM; Such, J; Zapater, P, 2015) |
| " For primary prophylaxis, short-term antibiotic treatment (oral norfloxacin or ciprofloxacin) is indicated in cirrhotic patients (with or without ascites) admitted with gastrointestinal haemorrhage (variceal or non-variceal)." | 4.84 | [Bacterial infections in liver cirrhosis]. ( Farkas, A; Papp, M; Tornai, I; Udvardy, M, 2007) |
| "For recipients who have received prophylactic norfloxacin, clinicians should be aware of the high risk of multidrug-resistant bacterial infections during the first month after liver transplant." | 4.31 | Impact of Prophylactic Norfloxacin in Multidrug Resistant Bacterial Infections in the Early Liver Posttransplant Period. ( Castells, L; Dopazo, C; Len, O; Lladó, L; Los-Arcos, I; Lung, M; Nuvials, X; Oriol, I; Pérez-Cameo, C; Sabé, N, 2023) |
| "Consecutively admitted patients with cirrhosis and ascitic fluid (AF) with: spontaneous bacterial peritonitis (SBP), non-infected AF, and norfloxacin as secondary SBP prophylaxis (SID group)." | 3.83 | Selective intestinal decontamination with norfloxacin enhances a regulatory T cell-mediated inflammatory control mechanism in cirrhosis. ( Caparrós, E; Francés, R; Giménez, P; Gómez-Hurtado, I; González-Navajas, JM; Juanola, O; Moratalla, A; Piñero, P; Such, J; Zapater, P, 2016) |
| "In cirrhotic rats with ascites: (a) pentoxifylline as well as norfloxacin reduced intestinal bacterial overgrowth and bacterial translocation and prevented spontaneous bacterial peritonitis; (b) pentoxifylline, but not norfloxacin, reduced oxidative stress in cecal mucosal." | 3.78 | Effects of pentoxifylline on intestinal bacterial overgrowth, bacterial translocation and spontaneous bacterial peritonitis in cirrhotic rats with ascites. ( Acevedo, J; Brusasco, C; Corradi, F; Fernández, J; Fernández-Varo, G; Gines, P; Mosbah, IB; Navasa, M; Pelosi, P; Ramirez, MJ; Rocco, PR; Seva-Pereira, T; Silva, A; Vila, J, 2012) |
| " Thirty patients were taking norfloxacin or trimethoprim-sulfamethoxazole as prophylaxis against bacterial peritonitis and 11 were not." | 3.76 | Effects of antibiotics on expression and function of Toll-like receptors 2 and 4 on mononuclear cells in patients with advanced cirrhosis. ( Angus, PW; Gow, PJ; Markovska, V; Skinner, N; Testro, AG; Visvanathan, K; Wongseelashote, S, 2010) |
| " The bactDNA translocation was investigated in 226 patients with cirrhosis and noninfected ascites, 22 patients with spontaneous bacterial peritonitis, and 10 patients with ascites receiving continuous norfloxacin." | 3.74 | Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis. ( Bellot, P; Caño, R; Francés, R; González-Navajas, JM; Moreu, R; Muñoz, C; Pascual, S; Pérez-Mateo, M; Such, J; Zapater, P, 2008) |
| "The objective of the study was to examine the characteristics of spontaneous bacterial peritonitis (SBP) caused by streptococci, in particular viridans group streptococci (VGS), and to investigate a potential association between the long-term administration of norfloxacin and high-level resistance to fluoroquinolones in these organisms." | 3.73 | Viridans group streptococci: an underestimated cause of spontaneous bacterial peritonitis in cirrhotic patients with ascites. ( Bert, F; Lambert-Zechovsky, N; Noussair, L; Valla, D, 2005) |
| "Norfloxacin decreases the incidence of spontaneous bacterial peritonitis in cirrhotics, but promotes the appearance of quinolone-resistant Escherichia coli." | 3.72 | Role of immunosuppression in the development of quinolone-resistant Escherichia coli spontaneous bacterial peritonitis and in the mortality of E. coli spontaneous bacterial peritonitis. ( Cereto, F; Del Valle, O; Esteban, R; Genescà, J; González, A; Guardia, J; Molina, I, 2003) |
| "Prophylaxis with norfloxacin has been shown to be effective in preventing spontaneous bacterial peritonitis (SBP) in liver cirrhosis." | 3.71 | Spontaneous bacterial peritonitis caused by quinolone-resistant Escherichia coli: could steroid therapy play a role? ( Cereto, F; del Valle Ortiz, O; Esteban, R; Genescà, J; González, A; Guardia, J; Moreno, G; Smithson, A, 2002) |
| "The extensive use of invasive procedures and of long-term norfloxacin prophylaxis in the management of cirrhotic patients may have influenced the epidemiology of bacterial infections in cirrhosis." | 3.71 | Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. ( Arroyo, V; Colmenero, J; Fernández, J; Gómez, J; Navasa, M; Rodés, J; Vila, J, 2002) |
| "We designed a prospective study to evaluate the incidence of Escherichia coli in stools at admission in patients with cirrhosis that had previously received norfloxacin as primary or secondary prophylaxis of spontaneous bacterial peritonitis (SBP) (group I, n = 28) vs those who did not (group II, n = 55)." | 3.70 | [Development of Escherichia coli strands resistant to quinolones in stools of patients with liver cirrhosis submitted to selective bowel decontamination]. ( Aparicio, JR; Arroyo, A; Gutiérrez, A; Pérez-Mateo, M; Plaza, J; Such, J, 1999) |
| "Spontaneous bacterial peritonitis in patients with and without prophylaxis with norfloxacin are not different in clinical features, response to treatment and prognosis." | 3.69 | Spontaneous bacterial peritonitis in patients with cirrhosis undergoing selective intestinal decontamination. A retrospective study of 229 spontaneous bacterial peritonitis episodes. ( Arroyo, V; Bataller, R; Cabré, E; Castells, A; Gassull, MA; Llovet, JM; Menacho, M; Moitinho, E; Navasa, M; Pardo, A; Planas, R; Rodés, J; Rodríguez-Iglesias, P, 1997) |
| " There was no difference among the studied groups regarding the incidence and severity of adverse events reported." | 2.82 | Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: a prospective randomized open-label comparative multicenter study. ( Abdelaziz, A; Abdelrashed, M; Assem, M; El-Azab, G; Elemam, S; Elsabaawy, M; Hamed, W; Khodeer, S, 2016) |
| "Norfloxacin therapy was not superior to placebo in reducing HVPG (13." | 2.74 | Norfloxacin treatment for clinically significant portal hypertension: results of a randomised double-blind placebo-controlled crossover trial. ( Chin-Dusting, J; Colman, J; Kemp, W; Kompa, A; Krum, H; Madan, A; Roberts, S; Thompson, K; Vincent, M, 2009) |
| "Bacterial infection was demonstrated in high percentage in patients with liver cirrhosis admitted to hospital." | 2.71 | Variceal bleeding in portal hypertension: bacterial infection and comparison of efficacy of intravenous and per-oral application of antibiotics--a randomized trial. ( Dastych, M; Díte, P; Husová, L; Juránková, J; Kroupa, R; Lata, J; Príbramská, V; Senkyrík, M, 2005) |
| "Due to a high number of bacterial infections antibiotics administration has been indicated in these patients." | 2.71 | [Factors participating in development of bleeding varices in portal hypertension. Part I: bacterial infection and comparison of intravenous and peroral antibiotics effects--a randomised study]. ( Dastych, M; Díte, P; Husová, L; Juránková, J; Lata, J; Príbramská, V; Senkyrík, M, 2004) |
| "Norfloxacin was not superior to other antibiotics." | 2.66 | Efficacy of Norfloxacin Prophylaxis to Prevent Spontaneous Bacterial Peritonitis: A Systematic Review and Meta-Analysis. ( Fernandez, J; Ferstl, PG; Graf, C; Herrmann, E; Lange, CM; Mücke, MM; Mücke, VT; Schwarzkopf, KM; Trebicka, J; Zeuzem, S, 2020) |
| "These studies reported a 1-year recurrence rate of 20-26%." | 1.51 | Spontaneous bacterial peritonitis recurrence in patients with cirrhosis receiving secondary prophylaxis with norfloxacin. ( Barcán, LA; Bermudez, C; Diaz, JM; Dirchwolf, M; Gadano, AC; Giunta, D; Gutierrez-Acevedo, MN; Marciano, S; Smud, A, 2019) |
| "The SBP recurrence rate was 42." | 1.37 | Recurrence of spontaneous bacterial peritonitis in cirrhotic patients non-prophylactically treated with norfloxacin: serum albumin as an easy but reliable predictive factor. ( Chen, WT; Chiu, CT; Ho, YP; Huang, CH; Lin, CY; Lin, TN; Sheen, IS, 2011) |
| "Norfloxacin was administered to reduce intestinal bacterial translocation." | 1.33 | Norfloxacin reduces aortic NO synthases and proinflammatory cytokine up-regulation in cirrhotic rats: role of Akt signaling. ( Bert, F; Cazals-Hatem, D; Dauvergne, A; Hervé, P; Lebrec, D; Moreau, R; Poirel, O; Rabiller, A; Tazi, KA, 2005) |
| "We performed a 5-year retrospective study to evaluate the effect of long-term administration of norfloxacin on the epidemiology of severe hospital-acquired infections in patients with advanced cirrhosis." | 1.30 | Epidemiology of severe hospital-acquired infections in patients with liver cirrhosis: effect of long-term administration of norfloxacin. ( Campillo, B; Dupeyron, C; Leluan, G; Mangeney, N; Richardet, JP, 1998) |
| "Treatment with norfloxacin induced the development of quinolone-resistant E." | 1.30 | Development of quinolone-resistant strains of Escherichia coli in stools of patients with cirrhosis undergoing norfloxacin prophylaxis: clinical consequences. ( Aparicio, JR; Arroyo, A; Carnicer, F; de Vera, F; Girona, E; Gutiérrez, A; Palazón, JM; Pascual, S; Pérez-Mateo, M; Plazas, J; Such, J, 1999) |
| "This study analyzes hospital acquired bacterial infections in cirrhotic patients with ascites and low levels of total protein in ascitic fluid (n = 53) and cirrhotic patients with gastrointestinal hemorrhage (n = 26), both submitted to selective intestinal decontamination with norfloxacin during the hospitalization." | 1.28 | [An analysis of hospital bacterial infections in cirrhotic patients undergoing selective intestinal decontamination]. ( Balanzó, J; Fábrega, E; Guarner, C; Méndez, C; Soriano, G; Such, J; Teixidó, M; Tena, F; Tomás, A; Villanueva, C, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.23) | 18.7374 |
| 1990's | 24 (29.63) | 18.2507 |
| 2000's | 27 (33.33) | 29.6817 |
| 2010's | 21 (25.93) | 24.3611 |
| 2020's | 8 (9.88) | 2.80 |
| Authors | Studies |
|---|---|
| Kulkarni, AV | 1 |
| Tirumalle, S | 1 |
| Premkumar, M | 1 |
| Kumar, K | 1 |
| Fatima, S | 1 |
| Rapole, B | 1 |
| Simhadri, V | 1 |
| Gora, BA | 1 |
| Sasikala, M | 1 |
| Gujjarlapudi, D | 1 |
| Yelamanchili, S | 1 |
| Sharma, M | 1 |
| Gupta, R | 2 |
| Rao, PN | 1 |
| Reddy, DN | 1 |
| Crocombe, D | 1 |
| Freemantle, N | 1 |
| O'Brien, A | 1 |
| Marciano, S | 2 |
| Gutierrez-Acevedo, MN | 2 |
| Barbero, S | 1 |
| Del C Notari, L | 1 |
| Agozino, M | 1 |
| Fernandez, JL | 1 |
| Anders, MM | 1 |
| Grigera, N | 1 |
| Antinucci, F | 1 |
| Orozco Ganem, OF | 1 |
| Murga, MD | 1 |
| Perez, D | 1 |
| Palazzo, A | 1 |
| Martinez Rejtman, L | 1 |
| Duarte, IG | 1 |
| Vorobioff, J | 1 |
| Trevizan, V | 1 |
| Bulaty, S | 1 |
| Bessone, F | 1 |
| Valverde, M | 1 |
| Elizondo, M | 1 |
| Bosia, JD | 1 |
| Borzi, SM | 1 |
| Stieben, TE | 1 |
| Masola, A | 1 |
| Ferretti, SE | 1 |
| Arufe, D | 1 |
| Demirdjian, E | 1 |
| Raffa, MP | 1 |
| Peralta, M | 1 |
| Fainboim, HA | 1 |
| Vazquez, CE | 1 |
| Ruiz, P | 1 |
| Martínez, JE | 1 |
| Heffner, LA | 1 |
| Odzak, A | 1 |
| Dirchwolf, M | 2 |
| Smud, A | 2 |
| Mendizabal, M | 1 |
| Bellizzi, C | 1 |
| Martinez, A | 1 |
| Tomatis, J | 1 |
| Bruno, A | 1 |
| Ramos, A | 1 |
| Pages, J | 1 |
| Tevez, S | 1 |
| Gadano, AC | 2 |
| Giunta, DH | 1 |
| Pérez-Cameo, C | 1 |
| Oriol, I | 1 |
| Lung, M | 1 |
| Lladó, L | 1 |
| Dopazo, C | 1 |
| Nuvials, X | 1 |
| Los-Arcos, I | 1 |
| Sabé, N | 1 |
| Castells, L | 1 |
| Len, O | 1 |
| Song, S | 1 |
| Yang, Y | 1 |
| Geng, C | 1 |
| Tang, Z | 1 |
| Wang, C | 1 |
| Li, X | 1 |
| Caparrós, E | 2 |
| Juanola, O | 2 |
| Gómez-Hurtado, I | 5 |
| Puig-Kroger, A | 1 |
| Piñero, P | 2 |
| Zapater, P | 10 |
| Linares, R | 1 |
| Tarín, F | 1 |
| Martínez-López, S | 1 |
| Gracia-Sancho, J | 1 |
| González-Navajas, JM | 6 |
| Francés, R | 9 |
| Mendoza, YP | 1 |
| Rodrigues, SG | 1 |
| Bosch, J | 1 |
| Berzigotti, A | 1 |
| Mücke, MM | 1 |
| Mücke, VT | 1 |
| Graf, C | 1 |
| Schwarzkopf, KM | 1 |
| Ferstl, PG | 1 |
| Fernandez, J | 6 |
| Zeuzem, S | 1 |
| Trebicka, J | 1 |
| Lange, CM | 1 |
| Herrmann, E | 1 |
| Yim, HJ | 1 |
| Suh, SJ | 1 |
| Jung, YK | 1 |
| Yim, SY | 1 |
| Seo, YS | 1 |
| Lee, YR | 1 |
| Park, SY | 1 |
| Jang, JY | 1 |
| Kim, YS | 1 |
| Kim, HS | 1 |
| Kim, BI | 1 |
| Um, SH | 1 |
| Moreau, R | 3 |
| Elkrief, L | 1 |
| Bureau, C | 1 |
| Perarnau, JM | 1 |
| Thévenot, T | 1 |
| Saliba, F | 1 |
| Louvet, A | 1 |
| Nahon, P | 1 |
| Lannes, A | 1 |
| Anty, R | 1 |
| Hillaire, S | 1 |
| Pasquet, B | 1 |
| Ozenne, V | 1 |
| Rudler, M | 1 |
| Ollivier-Hourmand, I | 1 |
| Robic, MA | 1 |
| d'Alteroche, L | 1 |
| Di Martino, V | 2 |
| Ripault, MP | 1 |
| Pauwels, A | 3 |
| Grangé, JD | 3 |
| Carbonell, N | 1 |
| Bronowicki, JP | 1 |
| Payancé, A | 1 |
| Rautou, PE | 1 |
| Valla, D | 2 |
| Gault, N | 1 |
| Lebrec, D | 3 |
| Diaz, JM | 1 |
| Bermudez, C | 1 |
| Barcán, LA | 1 |
| Giunta, D | 1 |
| Lombardi, A | 1 |
| Mondelli, MU | 1 |
| Bruno, R | 1 |
| Gupta, N | 1 |
| Kumar, A | 2 |
| Sharma, P | 1 |
| Garg, V | 1 |
| Sharma, BC | 1 |
| Sarin, SK | 3 |
| Saffouri, GB | 1 |
| Wittich, CM | 1 |
| Lontos, S | 1 |
| Shelton, E | 1 |
| Angus, PW | 2 |
| Vaughan, R | 1 |
| Roberts, SK | 1 |
| Gordon, A | 1 |
| Gow, PJ | 2 |
| Garcia-Martinez, I | 1 |
| Giménez, P | 2 |
| Moratalla, A | 2 |
| Lozano-Ruiz, B | 1 |
| Bellot, P | 5 |
| Such, J | 15 |
| Ramos, JM | 1 |
| Vidal, I | 1 |
| Mostafa, T | 1 |
| Badra, G | 1 |
| Abdallah, M | 1 |
| Salerno, F | 1 |
| La Mura, V | 1 |
| Assem, M | 1 |
| Elsabaawy, M | 1 |
| Abdelrashed, M | 1 |
| Elemam, S | 1 |
| Khodeer, S | 1 |
| Hamed, W | 1 |
| Abdelaziz, A | 1 |
| El-Azab, G | 1 |
| Elfert, A | 1 |
| Abo Ali, L | 1 |
| Soliman, S | 1 |
| Ibrahim, S | 1 |
| Abd-Elsalam, S | 1 |
| Kemp, W | 1 |
| Colman, J | 1 |
| Thompson, K | 1 |
| Madan, A | 1 |
| Vincent, M | 1 |
| Chin-Dusting, J | 2 |
| Kompa, A | 1 |
| Krum, H | 1 |
| Roberts, S | 1 |
| Caño, R | 3 |
| Llanos, L | 1 |
| Ruiz-Alcaraz, AJ | 1 |
| Pascual, S | 6 |
| Barquero, C | 1 |
| Moreu, R | 2 |
| Horga, JF | 1 |
| Muñoz, C | 3 |
| Pérez, J | 1 |
| García-Peñarrubia, P | 1 |
| Pérez-Mateo, M | 7 |
| Testro, AG | 1 |
| Wongseelashote, S | 1 |
| Skinner, N | 1 |
| Markovska, V | 1 |
| Visvanathan, K | 1 |
| Huang, CH | 1 |
| Lin, CY | 1 |
| Sheen, IS | 1 |
| Chen, WT | 1 |
| Lin, TN | 1 |
| Ho, YP | 1 |
| Chiu, CT | 1 |
| Corradi, F | 1 |
| Brusasco, C | 1 |
| Vila, J | 4 |
| Ramirez, MJ | 1 |
| Seva-Pereira, T | 1 |
| Fernández-Varo, G | 1 |
| Mosbah, IB | 1 |
| Acevedo, J | 1 |
| Silva, A | 1 |
| Rocco, PR | 1 |
| Pelosi, P | 1 |
| Gines, P | 3 |
| Navasa, M | 7 |
| Shah, N | 1 |
| Dhar, D | 1 |
| El Zahraa Mohammed, F | 1 |
| Habtesion, A | 1 |
| Davies, NA | 1 |
| Jover-Cobos, M | 1 |
| Macnaughtan, J | 1 |
| Sharma, V | 1 |
| Olde Damink, SWM | 1 |
| Mookerjee, RP | 1 |
| Jalan, R | 1 |
| Pande, C | 1 |
| Rabiller, A | 2 |
| Nunes, H | 1 |
| Tazi, KA | 2 |
| Wartski, M | 1 |
| Dulmet, E | 1 |
| Libert, JM | 1 |
| Mougeot, C | 1 |
| Mazmanian, M | 1 |
| Humbert, M | 1 |
| Hervé, P | 2 |
| Albillos, A | 1 |
| de la Hera, A | 1 |
| González, M | 1 |
| Moya, JL | 1 |
| Calleja, JL | 1 |
| Monserrat, J | 1 |
| Ruiz-del-Arbol, L | 1 |
| Alvarez-Mon, M | 1 |
| Cereto, F | 2 |
| Molina, I | 1 |
| González, A | 2 |
| Del Valle, O | 1 |
| Esteban, R | 2 |
| Guardia, J | 2 |
| Genescà, J | 2 |
| Rasaratnam, B | 1 |
| Connelly, N | 1 |
| Lata, J | 2 |
| Juránková, J | 2 |
| Husová, L | 2 |
| Senkyrík, M | 2 |
| Díte, P | 2 |
| Dastych, M | 2 |
| Príbramská, V | 2 |
| Gascón, I | 1 |
| Plazas, J | 2 |
| Sánchez, J | 1 |
| Más, P | 1 |
| Sandhu, BS | 1 |
| Sharma, J | 1 |
| Singh, J | 1 |
| Murthy, NS | 1 |
| Romney, R | 1 |
| Mathurin, P | 1 |
| Ganne-Carrié, N | 1 |
| Halimi, C | 1 |
| Medini, A | 2 |
| Lemaitre, P | 2 |
| Gruaud, P | 1 |
| Jouannaud, V | 1 |
| Delacour, T | 1 |
| Boudjema, H | 2 |
| Chaput, JC | 1 |
| Cadranel, JF | 3 |
| Dauvergne, A | 1 |
| Cazals-Hatem, D | 1 |
| Bert, F | 2 |
| Poirel, O | 1 |
| Noussair, L | 1 |
| Lambert-Zechovsky, N | 1 |
| Kroupa, R | 1 |
| Itha, S | 1 |
| Sharma, A | 1 |
| Bhatt, G | 1 |
| Ruiz del Arbol, L | 1 |
| Gómez, C | 1 |
| Durandez, R | 1 |
| Serradilla, R | 1 |
| Guarner, C | 9 |
| Planas, R | 5 |
| Arroyo, V | 4 |
| Papp, M | 1 |
| Farkas, A | 1 |
| Udvardy, M | 1 |
| Tornai, I | 1 |
| Márquez, D | 1 |
| Santana, F | 1 |
| Montoliu, S | 1 |
| Monfort, D | 1 |
| Soriano, G | 9 |
| Vila, C | 1 |
| Pardo, A | 2 |
| Quintero, E | 1 |
| Vargas, V | 3 |
| Runyon, BA | 1 |
| Schölmerich, J | 2 |
| Gerbes, AL | 1 |
| Andus, T | 1 |
| Leser, HG | 1 |
| Doershuk, CF | 1 |
| Stern, RC | 1 |
| el Aggan, HA | 1 |
| el-Aggan, HA | 1 |
| Abou Seif Helmy, M | 1 |
| Guirguis, TG | 1 |
| Imperiale, TF | 1 |
| Esber, EJ | 1 |
| Novella, M | 1 |
| Solà, R | 2 |
| Andreu, M | 2 |
| Gana, J | 2 |
| Ortiz, J | 3 |
| Coll, S | 2 |
| Sàbat, M | 3 |
| Vila, MC | 2 |
| Vilardell, F | 4 |
| Llovet, JM | 1 |
| Rodríguez-Iglesias, P | 1 |
| Moitinho, E | 1 |
| Bataller, R | 1 |
| Menacho, M | 1 |
| Castells, A | 1 |
| Cabré, E | 1 |
| Gassull, MA | 1 |
| Rodés, J | 4 |
| Glück, T | 1 |
| Campillo, B | 2 |
| Dupeyron, C | 2 |
| Richardet, JP | 3 |
| Mangeney, N | 1 |
| Leluan, G | 1 |
| Roulot, D | 1 |
| Pelletier, G | 1 |
| Pariente, EA | 1 |
| Denis, J | 2 |
| Ink, O | 1 |
| Blanc, P | 1 |
| Vinel, JP | 1 |
| Delisle, F | 1 |
| Fischer, D | 1 |
| Flahault, A | 1 |
| Amiot, X | 2 |
| Kolle, L | 1 |
| Pamplona, J | 1 |
| Novella, MT | 2 |
| Villanueva, C | 3 |
| Sainz, S | 2 |
| Torras, J | 1 |
| Balanzó, J | 3 |
| Miñana, J | 1 |
| Mirelis, B | 2 |
| Prats, G | 1 |
| Aparicio, JR | 2 |
| Arroyo, A | 2 |
| Girona, E | 1 |
| Gutiérrez, A | 2 |
| de Vera, F | 1 |
| Palazón, JM | 1 |
| Carnicer, F | 1 |
| Barbare, JC | 1 |
| Eugène, C | 1 |
| Poquet, E | 1 |
| Coutarel, P | 1 |
| Latrive, JP | 1 |
| Devergie, B | 1 |
| Jeffries, MA | 1 |
| Stern, MA | 1 |
| Gunaratnam, NT | 1 |
| Fontana, RJ | 1 |
| Plaza, J | 1 |
| Madrid, AM | 1 |
| Hurtado, C | 1 |
| Venegas, M | 1 |
| Cumsille, F | 1 |
| Defilippi, C | 1 |
| Smithson, A | 1 |
| Moreno, G | 1 |
| del Valle Ortiz, O | 1 |
| Gómez, J | 1 |
| Colmenero, J | 1 |
| Bauer, TM | 2 |
| Mofredj, A | 1 |
| Follo, A | 1 |
| Clemente, G | 1 |
| Bory, F | 1 |
| Vaquer, P | 1 |
| Tomás, A | 3 |
| Torras, X | 1 |
| González, D | 1 |
| Anguera, A | 2 |
| Cussó, X | 1 |
| Fernández, C | 1 |
| Herrero, M | 1 |
| Alonso, C | 1 |
| Schubert, ML | 1 |
| Sanyal, AJ | 1 |
| Wong, ES | 1 |
| Teixidó, M | 3 |
| Barrios, J | 2 |
| Enríquez, J | 2 |
| Méndez, C | 2 |
| Tena, F | 2 |
| Fábrega, E | 1 |
| Rimola, A | 1 |
| Marco, F | 1 |
| Almela, M | 1 |
| Forné, M | 1 |
| Miranda, ML | 1 |
| Llach, J | 1 |
| Salmerón, JM | 1 |
| Hoefs, JC | 1 |
| Rodríguez, JL | 1 |
| Silvain, C | 1 |
| Breux, JP | 1 |
| Rochard, E | 1 |
| Bouquet, S | 1 |
| Becq-Giraudon, B | 1 |
| Beauchant, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Double-Blind, Placebo-Controlled Trial Assessing Norfloxacin in the Prevention of Complications in Patients With Cirrhosis and Severe Liver Failure[NCT01037959] | Phase 3 | 291 participants (Actual) | Interventional | 2010-04-30 | Terminated (stopped due to lack of recruitement) | ||
| Rifaximin Prophylaxis Against Recurrence of Spontaneous Bacterial Peritonitis and Occurrence of Hepatorenal Syndrome in Decompensated Cirrhotic Egyptian Patients[NCT05621005] | Phase 2 | 104 participants (Actual) | Interventional | 2019-03-01 | Completed | ||
| Endoscopic and Microbiological Assessment of the Effect of Carvedilol Combined With Berberine on GOV in Cirrhosis: a Prospective Cohort Study[NCT04543643] | Phase 3 | 288 participants (Anticipated) | Interventional | 2021-11-01 | Not yet recruiting | ||
| The Efficacy and Safety of Rifaximin In The Treatment of HBV Associated Acute-on-Chronic Liver Failure Patients With Mild to Moderate Hepatic Encephalopathy[NCT05786859] | Early Phase 1 | 124 participants (Anticipated) | Interventional | 2023-03-09 | Recruiting | ||
| Clinical, Biochemical and Haemodynamic Effects of Large-volume Paracentesis (LVP) in Inflammatory Situations[NCT02799160] | 22 participants (Actual) | Observational | 2016-10-01 | Active, not recruiting | |||
| A Randomized, Double-blind, Placebo-controlled Pilot Study to Evaluate the Systemic Effect on Immunoinflammatory and Metabolic Status of an Oral Supplementation With AM3 in Patients With Metabolic Syndrome.[NCT06158152] | 48 participants (Anticipated) | Interventional | 2024-01-20 | Not yet recruiting | |||
| Comparison of 3 Days and 7 Days Intravenous Ceftriaxone Prophylaxis in Patients With Acute Variceal Bleeding[NCT00838864] | Phase 4 | 79 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| Asymptomatic Spontaneous Bacterial Peritonitis in Patients With Decompensated Liver Cirrhosis in Upper Egypt : A Prospective Hospital Based Study[NCT03163745] | 70 participants (Actual) | Observational | 2019-03-11 | Completed | |||
| Comparison of Daily Norfloxacin Versus Weekly Ciprofloxacin for the Prevention of Spontaneous Bacterial Peritonitis in Cirrhotic Patients[NCT01542801] | Phase 4 | 124 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| Rifaximin Versus Norfloxacin in the Primary Prophylaxis of Spontaneous Bacterial Peritonitis[NCT04159870] | Phase 3 | 322 participants (Anticipated) | Interventional | 2019-11-05 | Active, not recruiting | ||
| Patterns of Antibiotic Resistant Bacterial Infections in Liver Intensive Care Unit[NCT03855709] | 200 participants (Anticipated) | Observational | 2019-05-31 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for norfloxacin and Liver Cirrhosis
| Article | Year |
|---|---|
Norfloxacin versus alternative antibiotics for prophylaxis of spontaneous bacteria peritonitis in cirrhosis: a systematic review and meta-analysis.
Topics: Anti-Bacterial Agents; Humans; Liver Cirrhosis; Norfloxacin; Quinolones; Rifaximin | 2023 |
Effect of poorly absorbable antibiotics on hepatic venous pressure gradient in cirrhosis: A systematic review and meta-analysis.
Topics: Adrenergic beta-Antagonists; Anti-Bacterial Agents; Bacterial Translocation; Drug Therapy, Combinati | 2020 |
Efficacy of Norfloxacin Prophylaxis to Prevent Spontaneous Bacterial Peritonitis: A Systematic Review and Meta-Analysis.
Topics: Antibiotic Prophylaxis; Bacterial Infections; Drug Resistance, Multiple, Bacterial; Humans; Incidenc | 2020 |
Immunomodulating effects of antibiotics used in the prophylaxis of bacterial infections in advanced cirrhosis.
Topics: Animals; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteria; Bacterial Infections; Bacterial Tr | 2015 |
Nitric oxide and the hyperdynamic circulation in cirrhosis: is there a role for selective intestinal decontamination?
Topics: Anti-Bacterial Agents; Bacterial Translocation; Endotoxemia; Humans; Intestines; Liver; Liver Cirrho | 2004 |
[Bacterial infections in liver cirrhosis].
Topics: Administration, Oral; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Ascites; | 2007 |
[Spontaneous bacterial peritonitis in liver cirrhosis with ascites].
Topics: Anti-Bacterial Agents; Ascites; Bacteria; Bacterial Infections; Blood; Endoscopy; Humans; Leukocyte | 1995 |
[Spontaneous bacterial peritonitis].
Topics: Animals; Ascites; Bacterial Infections; Bacterial Translocation; Cefotaxime; Diagnosis, Differential | 1998 |
[Prophylaxis of infectious complications by selective digestive bacterial decontamination in patients with cirrhosis].
Topics: Anti-Bacterial Agents; Ascitic Fluid; Bacterial Infections; Decontamination; Digestive System Diseas | 1992 |
27 trials available for norfloxacin and Liver Cirrhosis
| Article | Year |
|---|---|
Primary Norfloxacin Prophylaxis for APASL-Defined Acute-on-Chronic Liver Failure: A Placebo-Controlled Double-Blind Randomized Trial.
Topics: Acute-On-Chronic Liver Failure; Bacterial Infections; Double-Blind Method; Humans; Liver Cirrhosis; | 2022 |
Daily Norfloxacin vs. Weekly Ciprofloxacin to Prevent Spontaneous Bacterial Peritonitis: A Randomized Controlled Trial.
Topics: Adult; Aged; Anti-Bacterial Agents; Ascites; Bacterial Infections; Ciprofloxacin; Disease-Free Survi | 2018 |
Effects of Long-term Norfloxacin Therapy in Patients With Advanced Cirrhosis.
Topics: Anti-Bacterial Agents; Ascites; Double-Blind Method; Female; France; Gram-Negative Bacterial Infecti | 2018 |
Effects of Long-term Norfloxacin Therapy in Patients With Advanced Cirrhosis.
Topics: Anti-Bacterial Agents; Ascites; Double-Blind Method; Female; France; Gram-Negative Bacterial Infecti | 2018 |
Effects of Long-term Norfloxacin Therapy in Patients With Advanced Cirrhosis.
Topics: Anti-Bacterial Agents; Ascites; Double-Blind Method; Female; France; Gram-Negative Bacterial Infecti | 2018 |
Effects of Long-term Norfloxacin Therapy in Patients With Advanced Cirrhosis.
Topics: Anti-Bacterial Agents; Ascites; Double-Blind Method; Female; France; Gram-Negative Bacterial Infecti | 2018 |
Effects of the adjunctive probiotic VSL#3 on portal haemodynamics in patients with cirrhosis and large varices: a randomized trial.
Topics: Adult; Analysis of Variance; Anti-Bacterial Agents; Biomarkers; Chi-Square Distribution; Combined Mo | 2013 |
A randomized controlled study of trimethoprim-sulfamethoxazole versus norfloxacin for the prevention of infection in cirrhotic patients.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotic Prophylaxis; Bacteremia; Bacterial I | 2014 |
The efficacy and the immunomodulatory effect of rifaximin in prophylaxis of spontaneous bacterial peritonitis in cirrhotic Egyptian patients.
Topics: Adult; Anti-Bacterial Agents; Ascites; Bacterial Infections; Female; Humans; Interleukin-10; Interle | 2015 |
Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: a prospective randomized open-label comparative multicenter study.
Topics: Adult; Aged; Antibiotic Prophylaxis; Bacterial Infections; Drug Administration Schedule; Female; Hum | 2016 |
Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ascites; Bacterial Infections; Cause of Death; Egypt; | 2016 |
Norfloxacin treatment for clinically significant portal hypertension: results of a randomised double-blind placebo-controlled crossover trial.
Topics: Anti-Bacterial Agents; Arginine; Cross-Over Studies; Endotoxemia; Humans; Hypertension, Portal; Live | 2009 |
Norfloxacin modulates the inflammatory response and directly affects neutrophils in patients with decompensated cirrhosis.
Topics: Aged; Anti-Bacterial Agents; Bacterial Infections; Cohort Studies; Cross-Over Studies; Cytokines; Fe | 2009 |
Addition of probiotics to norfloxacin does not improve efficacy in the prevention of spontaneous bacterial peritonitis: a double-blind placebo-controlled randomized-controlled trial.
Topics: Adolescent; Adult; Aged; Antibiotic Prophylaxis; Bacterial Infections; Combined Modality Therapy; Do | 2012 |
[Factors participating in development of bleeding varices in portal hypertension. Part I: bacterial infection and comparison of intravenous and peroral antibiotics effects--a randomised study].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Ampicillin; Anti-Bacterial Agents; Bacterial I | 2004 |
Norfloxacin and cisapride combination decreases the incidence of spontaneous bacterial peritonitis in cirrhotic ascites.
Topics: Adult; Analysis of Variance; Anti-Infective Agents; Ascites; Chi-Square Distribution; Cisapride; Dru | 2005 |
Variceal bleeding in portal hypertension: bacterial infection and comparison of efficacy of intravenous and per-oral application of antibiotics--a randomized trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Ampicillin; Anti-Bacterial Agents; Bacterial I | 2005 |
Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotic Prophylaxis; Ba | 2006 |
Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis.
Topics: Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Double-Blind Method; Female; Hepatorenal Syndro | 2007 |
Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis.
Topics: Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Double-Blind Method; Female; Hepatorenal Syndro | 2007 |
Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis.
Topics: Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Double-Blind Method; Female; Hepatorenal Syndro | 2007 |
Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis.
Topics: Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Double-Blind Method; Female; Hepatorenal Syndro | 2007 |
Selective intestinal decontamination in patients with schistosomal hepatic fibrosis and low-protein ascites.
Topics: Adult; Animals; Ascites; Ascitic Fluid; Humans; Intestines; Liver Cirrhosis; Norfloxacin; Peritoniti | 1993 |
Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin.
Topics: Anti-Infective Agents; Ascites; Bacterial Infections; Drug Administration Schedule; Drug Resistance, | 1997 |
Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial.
Topics: Adult; Aged; Anti-Infective Agents; Ascites; Double-Blind Method; Feces; Female; France; Gram-Negati | 1998 |
Parenteral antibiotic prophylaxis of bacterial infections does not improve cost-efficacy of oral norfloxacin in cirrhotic patients with gastrointestinal bleeding.
Topics: Administration, Oral; Aged; Anti-Infective Agents; Bacterial Infections; Ceftriaxone; Cephalosporins | 1998 |
Long-Term treatment with cisapride and antibiotics in liver cirrhosis: effect on small intestinal motility, bacterial overgrowth, and liver function.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Cisapride; Female; Gastrointest | 2001 |
Daily norfloxacin is more effective than weekly rufloxacin in prevention of spontaneous bacterial peritonitis recurrence.
Topics: Aged; Anti-Infective Agents; Female; Fluoroquinolones; Humans; Liver Cirrhosis; Male; Middle Aged; N | 2002 |
Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage.
Topics: Adult; Aged; Bacterial Infections; Female; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Mal | 1992 |
Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage.
Topics: Adult; Aged; Bacterial Infections; Female; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Mal | 1992 |
Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage.
Topics: Adult; Aged; Bacterial Infections; Female; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Mal | 1992 |
Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage.
Topics: Adult; Aged; Bacterial Infections; Female; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Mal | 1992 |
Antibiotic prophylaxis for prevention of spontaneous bacterial peritonitis?
Topics: Bacterial Infections; Cost-Benefit Analysis; Humans; Liver Cirrhosis; Norfloxacin; Peritonitis | 1991 |
Selective intestinal decontamination prevents spontaneous bacterial peritonitis.
Topics: Aged; Ascitic Fluid; Bacterial Infections; Female; Hospitalization; Humans; Intestines; Liver Cirrho | 1991 |
Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial.
Topics: Bacterial Infections; Double-Blind Method; Drug Administration Schedule; Feces; Female; Humans; Live | 1990 |
Selective intestinal decontamination increases serum and ascitic fluid C3 levels in cirrhosis.
Topics: Ascitic Fluid; Complement C3; Complement C4; Humans; Intestines; Liver Cirrhosis; Norfloxacin; Prote | 1990 |
45 other studies available for norfloxacin and Liver Cirrhosis
| Article | Year |
|---|---|
Additional Analyses for the Published Primary Norfloxacin Prophylaxis for APASL-Defined Acute-on-Chronic Liver Failure.
Topics: Acute-On-Chronic Liver Failure; Humans; Liver Cirrhosis; Norfloxacin | 2022 |
Norfloxacin prophylaxis effect on multidrug resistance in patients with cirrhosis and bacterial infections.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Cross-Sectional Studies; Drug R | 2023 |
Impact of Prophylactic Norfloxacin in Multidrug Resistant Bacterial Infections in the Early Liver Posttransplant Period.
Topics: Adult; Anti-Bacterial Agents; Bacterial Infections; End Stage Liver Disease; Humans; Liver Cirrhosis | 2023 |
Liver Sinusoidal Endothelial Cells Contribute to Hepatic Antigen-Presenting Cell Function and Th17 Expansion in Cirrhosis.
Topics: Adaptive Immunity; Animals; Antigen-Presenting Cells; Biomarkers; Cell Differentiation; Cell Membran | 2020 |
Spontaneous bacterial peritonitis recurrence in patients with cirrhosis receiving secondary prophylaxis with norfloxacin.
Topics: Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Female; Humans; Li | 2019 |
RE: Effects of Long-Term Norfloxacin Therapy in Patients With Advanced Cirrhosis.
Topics: Anti-Bacterial Agents; Humans; Liver Cirrhosis; Norfloxacin | 2019 |
83-year-old man with abdominal swelling and lower extremity edema.
Topics: Abdominal Cavity; Aged, 80 and over; Anti-Infective Agents; Ascites; Cefotaxime; Diagnosis, Differen | 2013 |
Use of proton pump inhibitors decrease cellular oxidative burst in patients with decompensated cirrhosis.
Topics: Aged; Bacterial Infections; Bacterial Translocation; Depression, Chemical; Drug Interactions; Female | 2015 |
Comparison of the in vitro susceptibility of rifaximin versus norfloxacin against multidrug resistant bacteria in a hospital setting. A proof-of-concept study for use in advanced cirrhosis.
Topics: Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Positive B | 2016 |
Treatment of Spontaneous Bacterial Peritonitis.
Topics: Age Factors; Albumins; Anti-Bacterial Agents; Antibiotic Prophylaxis; Ascites; Bilirubin; Drug Resis | 2015 |
Selective intestinal decontamination with norfloxacin enhances a regulatory T cell-mediated inflammatory control mechanism in cirrhosis.
Topics: Adoptive Transfer; Aged; Animals; Anti-Bacterial Agents; B7-1 Antigen; B7-2 Antigen; Bacterial Infec | 2016 |
Effects of antibiotics on expression and function of Toll-like receptors 2 and 4 on mononuclear cells in patients with advanced cirrhosis.
Topics: Adult; Aged; Anti-Bacterial Agents; Case-Control Studies; Female; Gram-Negative Bacterial Infections | 2010 |
Recurrence of spontaneous bacterial peritonitis in cirrhotic patients non-prophylactically treated with norfloxacin: serum albumin as an easy but reliable predictive factor.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Female; Humans; Liver Cirrhosis; Logistic Models; Male; | 2011 |
Interleukin-10-mediated heme oxygenase 1-induced underlying mechanism in inflammatory down-regulation by norfloxacin in cirrhosis.
Topics: Aged; Antibodies, Monoclonal; Cells, Cultured; Cyclooxygenase 2; DNA, Bacterial; Down-Regulation; Fe | 2011 |
Effects of pentoxifylline on intestinal bacterial overgrowth, bacterial translocation and spontaneous bacterial peritonitis in cirrhotic rats with ascites.
Topics: Analysis of Variance; Animals; Anti-Bacterial Agents; Ascites; Ascitic Fluid; Bacterial Translocatio | 2012 |
Prevention of acute kidney injury in a rodent model of cirrhosis following selective gut decontamination is associated with reduced renal TLR4 expression.
Topics: Acute Kidney Injury; Animals; Anti-Bacterial Agents; Cytokines; Disease Models, Animal; Gastrointest | 2012 |
Prevention of gram-negative translocation reduces the severity of hepatopulmonary syndrome.
Topics: Animals; Anti-Infective Agents; Antibiotic Prophylaxis; Bacterial Translocation; Common Bile Duct; D | 2002 |
Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement.
Topics: Acute-Phase Proteins; Anti-Infective Agents; Antigens, CD; Ascites; Blood Pressure; Carrier Proteins | 2003 |
Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement.
Topics: Acute-Phase Proteins; Anti-Infective Agents; Antigens, CD; Ascites; Blood Pressure; Carrier Proteins | 2003 |
Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement.
Topics: Acute-Phase Proteins; Anti-Infective Agents; Antigens, CD; Ascites; Blood Pressure; Carrier Proteins | 2003 |
Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement.
Topics: Acute-Phase Proteins; Anti-Infective Agents; Antigens, CD; Ascites; Blood Pressure; Carrier Proteins | 2003 |
Role of immunosuppression in the development of quinolone-resistant Escherichia coli spontaneous bacterial peritonitis and in the mortality of E. coli spontaneous bacterial peritonitis.
Topics: Anti-Infective Agents; Ascitic Fluid; Drug Resistance, Bacterial; Escherichia coli Infections; Human | 2003 |
Norfloxacin decreases bacterial adherence of quinolone-resistant strains of Escherichia coli isolated from patients with cirrhosis.
Topics: Anti-Infective Agents; Bacterial Adhesion; Drug Resistance, Bacterial; Escherichia coli; Humans; Inh | 2005 |
Usefulness of routine analysis of ascitic fluid at the time of therapeutic paracentesis in asymptomatic outpatients. Results of a multicenter prospective study.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Anti-Infective Agents; Antibiotic Prophylaxis; Asci | 2005 |
Norfloxacin reduces aortic NO synthases and proinflammatory cytokine up-regulation in cirrhotic rats: role of Akt signaling.
Topics: Animals; Aorta; Bacterial Translocation; Enzyme Inhibitors; Feces; Liver Cirrhosis; Male; Nitric Oxi | 2005 |
Viridans group streptococci: an underestimated cause of spontaneous bacterial peritonitis in cirrhotic patients with ascites.
Topics: Anti-Bacterial Agents; Ascitic Fluid; Drug Administration Schedule; Drug Resistance, Bacterial; Fema | 2005 |
Norfloxacin and cisapride combination decreases the incidence of spontaneous bacterial peritonitis in cirrhotic ascites.
Topics: Anti-Infective Agents; Ascites; Bacterial Infections; Cisapride; Drug Therapy, Combination; Gastroin | 2006 |
Bacterial DNA induces the complement system activation in serum and ascitic fluid from patients with advanced cirrhosis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ascites; Ascitic Fluid; Bacterial Infections; | 2007 |
A pill a day can improve survival in patients with advanced cirrhosis.
Topics: Anti-Infective Agents; Antibiotic Prophylaxis; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Norflo | 2007 |
Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis.
Topics: Adult; Aged; Anti-Bacterial Agents; Ascites; Bacterial Infections; DNA, Bacterial; Female; Humans; I | 2008 |
Spontaneous bacterial peritonitis in cystic fibrosis.
Topics: Adolescent; Adult; Bacterial Infections; Cystic Fibrosis; Female; Humans; Liver Cirrhosis; Male; Nor | 1994 |
Preventing infection in cirrhotics with gastrointestinal hemorrhage.
Topics: Bacteremia; Bacterial Infections; Biometry; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; No | 1993 |
Spontaneous bacterial peritonitis in patients with cirrhosis undergoing selective intestinal decontamination. A retrospective study of 229 spontaneous bacterial peritonitis episodes.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacterial Translocation; Female; Humans; Inci | 1997 |
Epidemiology of severe hospital-acquired infections in patients with liver cirrhosis: effect of long-term administration of norfloxacin.
Topics: Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Ascitic Fluid; Bacteremia; Cross Infection; Dru | 1998 |
Infections caused by Escherichia coli resistant to norfloxacin in hospitalized cirrhotic patients.
Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Ciprofloxacin; Drug Resi | 1999 |
Development of quinolone-resistant strains of Escherichia coli in stools of patients with cirrhosis undergoing norfloxacin prophylaxis: clinical consequences.
Topics: Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Cross Infection; Drug Resistance, Microbial; Es | 1999 |
Prevalence and risk factors of bacteriuria in cirrhotic patients: a prospective case-control multicenter study in 244 patients.
Topics: Anti-Infective Agents; Case-Control Studies; Female; Humans; Liver Cirrhosis; Male; Microbial Sensit | 1999 |
Unsuspected infection is infrequent in asymptomatic outpatients with refractory ascites undergoing therapeutic paracentesis.
Topics: Adult; Aged; Ambulatory Care; Anti-Infective Agents; Antibiotic Prophylaxis; Ascites; Ascitic Fluid; | 1999 |
[Development of Escherichia coli strands resistant to quinolones in stools of patients with liver cirrhosis submitted to selective bowel decontamination].
Topics: Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Escherichia coli; Escherichia coli Infections; | 1999 |
Spontaneous bacterial peritonitis caused by quinolone-resistant Escherichia coli: could steroid therapy play a role?
Topics: Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Drug Resistance, Bacterial; Escherichia coli; E | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Critical Care; Drug Resistance, Microbial; Escher | 2002 |
Epidemiology of hospital-acquired infections in cirrhotic patients: effect of carriage of methicillin-resistant Staphylococcus aureus and influence of previous antibiotic therapy and norfloxacin prophylaxis.
Topics: Anti-Infective Agents; Bacterial Infections; Carrier State; Cross Infection; Female; France; Humans; | 2001 |
Failure of Lactobacillus spp. to prevent bacterial translocation in a rat model of experimental cirrhosis.
Topics: Animals; Anti-Bacterial Agents; Ascitic Fluid; Bacteria; Bacterial Infections; Bacterial Translocati | 2002 |
Norfloxacin-induced eosinophilia in a cirrhotic patient.
Topics: Adult; Drug Administration Schedule; Eosinophilia; Humans; Liver Cirrhosis; Male; Norfloxacin | 2002 |
[The duration of the effect of norfloxacin on the fecal flora in cirrhosis patients].
Topics: Administration, Oral; Drug Evaluation; Feces; Gram-Negative Aerobic Bacteria; Gram-Negative Bacteria | 1992 |
[An analysis of hospital bacterial infections in cirrhotic patients undergoing selective intestinal decontamination].
Topics: Ascites; Bacterial Infections; Cross Infection; Decontamination; Female; Humans; Incidence; Intestin | 1991 |
Spontaneous bacterial peritonitis: prevention and therapy.
Topics: Anti-Bacterial Agents; Bacterial Infections; Humans; Liver Cirrhosis; Norfloxacin; Peritonitis | 1990 |
Decreased erythrocyte penetration of pefloxacin in cirrhotic patients.
Topics: Adult; Aged; Anti-Infective Agents; Blood Proteins; Erythrocytes; Female; Humans; Liver Cirrhosis; M | 1987 |